Sansei Landic : Supplementary Materials for Consolidated Financial Results for 2Q of FY12/21

Sansei Landic Co., Ltd.

Supplementary Materials for

Consolidated Financial Results for

2Q of FY12/21

August 12, 2021

FY12/21 2Q Topics

• Business forecasts revised upward as both sales and profits exceeded the plan and the year-on-year results
• Purchase amount fell below the year-on-year results and plan but the current purchase situation is favorable as the number of projects and number of purchasing contracts are increasing
• Construction business fell below the plan and the year-on-year results Disclosed the results of investigation as of today regarding our subsidiary's "Possibility of Inappropriate Transactions" released in June. Decided not to make retroactive adjustments in previous years as the effects on prior consolidated financial results are considered to

be minimal*

*As stated in the "Notice of Absorption-type Merger of Subsidiary (Simplified Merger and Absorption-type Merger) and Discontinuation of Debt Waiver" as of June 28, 2021, we found out that inappropriate transactions may have been conducted at our consolidated subsidiary One's Life Home. Accordingly, we established an internal investigation committee and

have been investigating this matter. We disclosed the results of investigation in the "Results of Investigation into Inappropriate Transactions by a Subsidiary and Future Policy" released today.

1

Our Response to COVID-19

We will continue to respond flexibly to prevent the spread of COVID-19.

Response to our clients	Response to our employees
・During the spread of COVID-19, conduct PCR tests before	・Provide masks for all employees
visiting customers and thoroughly implement measures	・Continue remote working and staggered work hours
against infections such as wearing masks when seeing
customers	・Lend computers and printers, etc. for remote working
・Conduct telephone and online meetings
・Promotion of online application procedures
・Refrain from holding and participating in face-to-face
・Conduct antibody tests
seminars
・Refrain from holding and participating in business dinners	・Conduct regular PCR tests
and social gatherings	・Establishment of vaccine leave
・Installation of air purifiers on each floor including reception
・Installation of carbon dioxide meters on each floor including
reception
・Apply antiviral agents and antibacterial finishing on each
floor including reception

2

Financial Results

(Unit: Million yen)

		19/2Q	20/2Q		21/2Q
		Results	Results	Plan	Results	Vs. plan
	Net sales	7,701	8,354	8,375	9,109	+734
	Gross profit	2,341	1,931	1,960	2,331	+371
	SG&A	1,550	1,535	1,674	1,642	-31
	Operating	790	395	286	689	+402
	income
	Ordinary	750	291	214	631	+416
	income
	Net income	473	182	137	402	+265

■ Net sales

+9.0% YoY

■ Gross profit

+20.7% YoY

■ Operating income

+74.3% YoY

■ Ordinary income

+116.4% YoY

■ Net income

+120.8% YoY

3

Summary of Consolidated Balance Sheet

				(Unit: Million yen)
	FY12/20		21/2Q
	Amount	Amount	Vs. end of	Pct. change
	previous term
Cash and
4,329	4,281	-48	-1.1%
deposits
Property for	14,424	12,586	-1,838	-12.7％
sale
Interest-bearing	8,341	6,587	-1,754	-21.0
liabilities
Net assets	10,066	10,093	+26	+0.3％
Total assets	20,070	18,425	-1,645	-8.2％
Shareholders'	50.1%	54.8%	+4.7pt	―
equity ratio

• Property for sale

Decreased compared with the end of the previous fiscal year due to steady sales Sales for FY12/20 2Q:

8,354 million yen Sales for FY12/21 2Q: 9,109 million yen

• Interest-bearingliabilities

Decreased compared with the end of the previous fiscal year due to increase in sales

4